SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 30th, 2016 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2016, between Stellar Biotechnologies, Inc., a British Columbia corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 6th, 2020 • Edesa Biotech, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 6, 2020, between Edesa Biotech, Inc., a British Columbia corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 15th, 2018 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 11, 2018, between Stellar Biotechnologies, Inc., a British Columbia corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 23rd, 2022 • Edesa Biotech, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 21, 2022, between Edesa Biotech, Inc., a company incorporated under the laws of British Columbia, Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SERIES A COMMON SHARE PURCHASE WARRANT stellar biotechnologies, inc.Stellar Biotechnologies, Inc. • May 30th, 2018 • Pharmaceutical preparations • New York
THIS SERIES A COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 29, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Stellar Biotechnologies, Inc., a British Columbia corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common shares, no par value per share (the “Common Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON SHARE PURCHASE WARRANT EDESA BIOTECH, INC.Edesa Biotech, Inc. • December 15th, 2023 • Pharmaceutical preparations • New York
THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 7, 2024 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Edesa Biotech, Inc., a British Columbia corporation (the “Company”), up to [●] shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common shares, no par value per share (the “Common Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
STRICTLY CONFIDENTIAL Stellar Biotechnologies, Inc.Letter Agreement • April 17th, 2018 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • New York
SHAREHOLDER RIGHTS PLAN AGREEMENT DATED AS OF JANUARY 9, 2014 BETWEEN STELLAR BIOTECHNOLOGIES, INC. AND COMPUTERSHARE INVESTOR SERVICES INC.Shareholder Rights Plan Agreement • November 14th, 2014 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • British Columbia
MEMORANDUM OF AGREEMENT, dated as of January 9, 2014 between Stellar Biotechnologies, Inc. (the “Company”), a company continued under the laws of British Columbia and Computershare Investor Services Inc., a corporation existing under the laws of Canada (the “Rights Agent”);
Edesa Biotech, Inc. 1,562,500 Common Shares (no par value per share) Amended and Restated Underwriting AgreementEdesa Biotech, Inc. • February 26th, 2021 • Pharmaceutical preparations • New York
Edesa Biotech, Inc., a company incorporated under the laws of British Columbia, Canada (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 1,562,500 of its common shares (the “Firm Shares”), no par value per share (the “Common Shares”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional 234,375 Common Shares as provided in Section 2. The additional 234,375 Common Shares that may be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” H.C. Wainwright & Co., LLC (“Wainwright”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters l
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • May 30th, 2018 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of May 24, 2018, is by and between Stellar Biotechnologies, Inc., a British Columbia corporation (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of warrants to purchase shares of the Company’s common stock, no par value per share (the “Common Stock”), issued by the Company, which warrants are exercisable at an exercise price of $2.65 per share (the “Original Warrants”).
Employment AgreementEmployment Agreement • June 27th, 2023 • Edesa Biotech, Inc. • Pharmaceutical preparations
WHEREAS the Employer wishes to offer employment to the Employee on the terms and conditions set out in this Employment Agreement ("Agreement") and the Employee wishes to accept the offer of employment;
BOARD of DIRECTORS SERVICE AGREEMENTBoard of Directors Service Agreement • February 3rd, 2012 • Stellar Biotechnologies, Inc. • California
THIS BOARD of DIRECTORS SERVICE AGREEMENT ("Agreement") is made as of January 1, 2012, by and between Stellar Biotechnologies, Inc., a California corporation (the "Company"), and Daniel E, Morse, Ph. D.("Director").
TSX VENTURE EXCHANGE FORM 2F CPC ESCROW AGREEMENTEscrow Agreement • February 3rd, 2012 • Stellar Biotechnologies, Inc.
This Agreement is being entered into by the Parties under Exchange Policy 2.4 - Capital Pool Companies (the Policy) in connection with a listing of a Capital Pool Company on the TSX Venture Exchange (the Exchange).
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • July 9th, 2012 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations
STELLAR BIOTECHNOLOGIES, Inc., a corporation duly organized under and pursuant to the laws of California, USA, and having its principal offices at 321E. Hueneme Rd, #170 Port Hueneme, CA 93041, USA, (hereinafter referred to as “STELLAR”)
Amended and Restated Employment AgreementEmployment Agreement • August 9th, 2023 • Edesa Biotech, Inc. • Pharmaceutical preparations
THIS AMENDED AND RESTATED AGREEMENT is made as of August 4, 2023 (the “Agreement”) and amends and replaces in its entirely the employment agreement between the Company (as defined below) and the Employee (as defined below) made as of June 14, 2019, as amended on March 19, 2021 and April 12, 2022 (the “Old Employment Agreement”);
the “Corporation”) PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (CDN $0.25 UNITS) INSTRUCTIONS TO SUBSCRIBERSubscription Agreement • September 9th, 2015 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • British Columbia
All Subscribers must sign and deliver to Stellar Biotechnologies, Inc. at its Canadian office, 1868 King George Blvd., South Surrey, British Columbia, V4A 5A1 (Tel: 604-306-8854 / Fax: 604-535-4454):
Edesa Biotech, Inc. Common Shares, without par value, Having an Aggregate Offering Price of up to US$20,000,000 EQUITY DISTRIBUTION AGREEMENTEdesa Biotech, Inc. • March 27th, 2023 • Pharmaceutical preparations • New York
Edesa Biotech, Inc., a company incorporated pursuant to the laws of the Province of British Columbia, Canada (the “Company”), confirms this agreement (this “Agreement”) with Canaccord Genuity LLC (the “Manager”) as follows:
CLASS A COMMON SHARE PURCHASE WARRANT Edesa Biotech, Inc.Edesa Biotech, Inc. • November 3rd, 2022 • Pharmaceutical preparations
THIS CLASS A COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any date that is the earlier to occur of 60 days from November 2, 2022 (the “Closing Date”) or the date a registration statement for the Company’s common shares (“Common Shares”) is declared effective (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (Toronto time) on the third (3rd) anniversary of the Initial Exercise Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Edesa Biotech, Inc., a British Columbia corporation (the “Company”), up to [●] Common Shares under this Warrant (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Edesa Biotech, Inc. Common Shares, without par value, Having an Aggregate Offering Price of up to $9,200,000 USD EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • September 28th, 2020 • Edesa Biotech, Inc. • Pharmaceutical preparations • New York
NON-BROKERED PRIVATE PLACEMENT OF UNITS SUBSCRIPTION AGREEMENT INSTRUCTIONSSubscription Agreement • November 3rd, 2022 • Edesa Biotech, Inc. • Pharmaceutical preparations • Ontario
EDESA BIOTECH, INC.Indemnity Agreement • June 20th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations • British Columbia
such capacities referred to herein as the "Indemnified Capacities", the Corporation with full power and authority to grant an indemnity valid and binding upon and enforceable against it in the terms hereinafter contained, hereby agrees to indemnify you to the full extent contemplated by this Agreement.
NON-BROKERED PRIVATE PLACEMENT OF UNITS SUBSCRIPTION AGREEMENT INSTRUCTIONSSubscription Agreement • November 3rd, 2022 • Edesa Biotech, Inc. • Pharmaceutical preparations • Ontario
SUBJECT: LETTER AGREEMENT/LEASE AMENDMENT 1 WITH RESPECT TO EXTENSION OF LEASE TERM AND ESTABLISHMENT OF NEW BASE RENT FOR UNITS #4 AND #5 AND ESTABLISHMENT OF NEW COMMENCEMENT DATE FOR UNIT #7 OF THE PORT HUENEME AQUACUL TUIRE CENTERStellar Biotechnologies, Inc. • December 14th, 2015 • Pharmaceutical preparations
In accordance with Paragraph 58 of the Addendum to that certain Sublease, dated October 2, 2000, by and between Stellar Biotechnologies, Inc. ("Stellar'') and the Port Hueneme Surplus Property Authority ("SPA") for Units #3, #4, and
ESCROW AGREEMENT VALUE SECURITY;Escrow Agreement Value Security; • February 3rd, 2012 • Stellar Biotechnologies, Inc. • British Columbia
This Agreement is being entered into by the Parties under Exchange Policy 5.4 - Escrow, Vendor Consideration and Resale Restrictions (the Policy) in connection with a Qualifying Transaction. The Issuer is a Tier 2 Issuer as described in Policy 2.1 - Minimum Listing Requirement & For, good and valuable consideration, the Parties agree as follows:
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 15th, 2023 • Edesa Biotech, Inc. • Pharmaceutical preparations
This First Amendment (“First Amendment”), effective as of September 21, 2023 (“Effective Date”), is entered into by and between Saul Yedgar, an individual with principal residence at [**] (“LICENSOR”), and Edesa Biotech Research Inc., an Ontario corporation with its principal office at 100 Spy Court, Markham, Ontario, L4R 5H6 (“EDESA”). LICENSOR and EDESA may be referred to herein individually as a “Party” or collectively as the “Parties”. Reference to a Party shall be deemed to include that Party’s Affiliates.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Execution Version: 29/06/16 EXCLUSIVE LICENSE AGREEMENT by and between...Exclusive License Agreement • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations • London
This Agreement ("Agreement"), effective as of June 29, 2016 ("Effective Date"), is entered into by and between Yissum Research Development Company of the Hebrew University of Jerusalem, an Israeli corporation with its principal office at Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390 Israel ("YISSUM"), and Edesa Biotech Inc., an Ontario corporation with its principal office at I 00 Spy Court, Markham, Ontario, L3R 5H6 ("EDESA"). YISSUM and EDESA may be referred to herein individually as a "Party" or collectively as the "Parties". Reference to a Party shall be deemed to include that Patty's Affiliates.
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 14th, 2021 • Edesa Biotech, Inc. • Pharmaceutical preparations
Collaboration AgreementCollaboration Agreement • July 30th, 2015 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • California
This COLLABORATION AGREEMENT (the “Agreement”) is entered into and effective as of July 27, 2015 (the “Effective Date”), by and between Stellar Biotechnologies Inc., a California corporation (“SBI”), and Ostiones Guerrero, SA de CV (“OG”). SBI and OG are referred to individually herein from time to time as a “Party,” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***”. JOINT VENTURE AGREEMENT dated By and Among NEOVACS, S.A. AND STELLAR BIOTECHNOLOGIES, INC. Confidential Treatment...Joint Venture Agreement • May 17th, 2016 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations
MANUFACTURING AND SUPPLY AGREEMENT Stellar Biotechnologies, Inc. and Life Diagnostics, Inc.Manufacturing and Supply Agreement • July 5th, 2012 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations
Life Diagnostics, Inc., a Pennsylvania corporation with administrative offices at 906 Old Fern Hill Road, West Chester, PA 19380 (“LIFE DX”) and Stellar Biotechnologies, Inc., a Canadian corporation having a place of business at 332 E. Scott Street, Port Hueneme, CA 93041 (”STELLAR”), together “The Parties”, agree as follows:
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations
This First Amendment ("First Amendment"), effective as of April 3, 2017 ("Effective Date"), is entered into by and between Yissum Research Development Company of the Hebrew University of Jerusalem, an Israeli corporation with its principal office at Hi-Tech Park, Edmond
ADVISORY BOARD MEMBER CONSULTING AGREEMENTAdvisory Board Member Consulting Agreement • February 3rd, 2012 • Stellar Biotechnologies, Inc. • California
THIS ADVISORY BOARD MEMBER CONSULTING AGREEMENT (“Agreement") is made as of June 15, 2010, by and between Stellar Biotechnologies, Inc., a California corporation (the "Company"), and Malcolm Gefter, Ph. D.("Consultant").
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 14th, 2021 • Edesa Biotech, Inc. • Pharmaceutical preparations
This agreement (the “Amendment”) is entered into by and between Kathi Niffenegger (“Employee”) and Edesa Biotech USA, Inc. (the “Company”) to amend the employment agreement entered into by Employee and the Company as of December 1, 2020 (the “Agreement”), and shall be effective as of the date executed by the parties. For good and valuable consideration, the sufficiency of which is hereby acknowledged, the Employee and the Company agree as follows:
LEASE (COMMERCIAL)Lease • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations
In consideration of the rents, covenants and obligations stipulated herein the Landlord and the Tenant have agreed to enter into a lease of certain offices in the building (the "Building") located at 100 Spy Court, Markham, ON, consisting of approximately 2,800 square feet as more particularly shown on Schedule "A"
SECOND AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 13th, 2022 • Edesa Biotech, Inc. • Pharmaceutical preparations
